[One of the many helpful things Ed Silverman does on is publish Pharmalot op-eds from the people in the know. This one is about the Roche·Tamiflu·Cochrane Collaboration controversy]. Trial Data Down The Rabbit Hole: Heneghan Explains Pharmalot By Ed Silverman March 4th, 2013 Last week, Roche responded to criticism over its handling of Tamiflu clinical […]
[link] New opportunities for treatment development. The enormous expansion of the medication portfolio for mental disorders between 1980 and 2000 was limited to a relatively narrow space of biology. Over the past decade, a new focus on the genetics and neurobiology of these disorders has generated a range of new targets for next-generation treatments. In […]
It has been a little over a year since Allen Jones and the State of Texas v. Johnson & Johnson et al [the TMAP Trial] in Austin Texas. I had by then spent a couple of years blogging about the corruption in the psychopharmacologic industry, and I flew out for the trial. Frankly, my reason […]
In closely reading many of the Clinical Trials of the psychoactive drugs in the last thirty years, I found that the majority put varying levels of spin on the data. I didn’t expect that. I had spent my medical life believing that the Journal editing process and peer review process was a system that wouldn’t […]
DSM-5 and the Sorry State of American Psychiatry Hooked by Howard Brodie February 28, 2013 If you think I’ve been underproducing blog posts lately, you can lay the blame at the doorstep of Rick Bukata and Jerry Hoffman of Primary Care Medical Abstracts. Being a lazy cuss, I often don’t know that an article of […]
Apparently, the good news reported from Roche about the Tamiflu Clinical Trial Data wasn’t such good news after all [good news…]. Roche says it will not relinquish control over access to clinical trial data British Medical Journal via Pharmagossip By Zosia Kmietowicz March 1, 2013 Campaigners for full transparency of all clinical trial data have […]
The ABPI’s first response was to reject the claims contained in Bad Pharma saying they were historical – a response widely seen as inadequate – but the industry organisation is now making moves to ensure pharma companies comply with existing pledges to publish data. Ben Goldacre versus Stephen Whitehead Debate There is little more infuriating […]
Getting Past the Grief over Grief Scientific American By Sidney Zisook February 25, 2013 These days, I get a lot of grief about grief. I am part of the work group that changed some of the ways that grief and clinical depression are described and differentiated in the new Diagnostic and Statistical Manual of Mental […]
PharmaTimes head-to-head debate Whitehead vs Goldacre 26 February, 2013, 5.15pm The Royal Institution, Albemarle Street, London Does pharma put profits ahead of patients? Is the industry failing to live up to the legal and moral standards expected of it? Or do its criticisers continue to push historical examples of malpractice and fail to recognise the […]
While the details aren’t totally clear to me, Pharmalot is reporting a red letter day for the cause of Clinical Trial transparency. Tamiflu, a treatment to ameliorate the intensity of flu symptoms has been stockpiled to the tunes of billions of dollars in anticipation of a flu epidemic. When the Cochrane Group wanted to do […]